Overview of new approaches that aim to improve outcomes for patients with chronic lymphocytic leukemia (CLL) presented at the ESH 3^rd Translational Research Conference: Chronic Lymphocytic Leukaemia.

The Satellite Symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.

A video about the mode of action (MoA) of PD-1 inhibitors.

Professor Tam discusses some common chronic lymphocytic leukemia (CLL) disease characteristics and expected treatment outcomes. He introduces the role of Bruton's tyrosine kinase inhibition (BTKi) in CLL, challenges in their use, and hopes for the future treatment of CLL.

BeiGene wants to ensure access to medicines for all patients and puts patients first in the fight against cancer. We foster strong collaborations that extend to the farthest reaches of the globe. Learn more about the BeiGene story.